Industrial Laser Distance Sensor
Industrial
Laser Distance Sensor, we also call it secondary development laser distance
module, which support TTL level and CMOS. The laser range sensor can be widely
used in professional surveying, mapping, construction, robots, hunting arrows,
industrial monitoring and automated measurement applications in electricity,
transportation, etc. Our laser distance module supports data communication with
RS232, USB with a simple adapter. The results of laser distance sensor can be
evaluated with Arduino. We are always looking ahead, hoping we can make every
measurement simple in life!
Parameters
of M703A:
Accuracy
±1
mm (0.04 inch)
Measuring
Unit
meter/inch/feet
Measuring
Range (without Reflection)
0.03-150m
Measuring
Time
0.1~3
seconds
Laser
Class
Class
II
Laser
Type
635nm,
<1mW
Size
72*40*18mm
(±1 mm)
Weight
About
21g
Voltage
DC2.0~3.3V
Electrical
Level
TTL/CMOS
Frequency
10Hz
Operating
Temperature
0-40 ℃ (32-104 ℉ )
Storage
Temperature
-25~60 ℃ (-13~140 ℉)
Laser Distance RS232,Arduino Distance Module,Laser Module RS232 Chengdu JRT Meter Technology Co., Ltd , https://www.cdlaserdistancemeter.com
Hervé Hoppenot, president of Novartis's oncology department, said: “Evermustus is the first drug to combine hormonal therapies for the treatment of ER+HER-2 advanced breast cancer patients. These cancers still have unmet clinical needs. Hormone therapy is resistant, and the magnitude of the benefits seen in these patients suggests that everolimus is a potentially important new treatment."
BOLERO-2 (oral everolimus 2 breast cancer test) testing everolimus combined with exemestane and exemestane alone for ER+ HER2-recurrent breast cancer recurrence or worsening or previously receiving letrozole or anastrozole The safety and efficacy of hormone therapy in postmenopausal women. The results of the trial were presented at a chairperson seminar for the 2011 European Multidisciplinary Cancer Symposium held in Stockholm, Sweden. 
A key phase 3 study shows that Afinitor (everolimus) tablets combined with the hormone drug exemestane prolongs survival of women without tumor growth compared with exemestane alone in patients with advanced breast cancer (Progression-free survival, PFS) was more than 2 times, and significantly reduced the risk of cancer deterioration by 57%.